Lilly Just Dropped $2.3 Billion on a Drug With Zero Human Data

But they're more like painkillers than cures. They manage symptoms without truly modifying the underlying disease. Many patients see their responses fade over time, and survival benefits remain limited. For a disease that can progress to acute leukemia, "your spleen is smaller" isn't exactly a mic drop.

Worse, JAK inhibitors used for chronic inflammatory conditions carry FDA boxed warnings (the agency's most serious safety label) for heart events, blood clots, cancer risk, and death. Those warnings stem from a landmark trial called ORAL Surveillance, which flagged these risks in rheumatoid arthritis patients taking tofacitinib. The FDA then applied the warnings across JAK inhibitors used in those settings, though JAK inhibitors approved for blood disorders like ruxolitinib and fedratinib are excluded. It cast a long shadow over the whole class.

The Type II Twist

This is where Ajax's science gets interesting.

Every approved JAK inhibitor works the same basic way: they bind to the active form of the JAK2 protein. Scientists call this the "Type I" conformation. Think of it like trying to stop a spinning fan by jamming your hand into the blades. It works, but it's messy, and the fan eventually finds a way to keep spinning.

AJ1-11095 takes a different approach. It binds to the inactive form of JAK2 (the "Type II" conformation). Instead of fighting a spinning fan, you're flipping the off switch. In preclinical studies, this translated into significant reductions in mutant cell burden, bone marrow scarring, and inflammatory signals that drive the disease forward. It also showed activity against cells that had become resistant to standard Type I inhibitors.

The drug was designed in collaboration with Schrödinger, the computational chemistry company, using structure-based drug design. Ajax Therapeutics presented preclinical results for AJ1-11095 at the American Society of Hematology (ASH) meeting in December 2025, and those results were compelling enough for Lilly to invest in Ajax's $95 million Series C round that same year.

Now they're buying the whole company.

Phase 1 and Prayers

AJ1-11095 is currently in a Phase 1 trial (the earliest stage of human testing) enrolling myelofibrosis patients whose disease worsened on existing JAK inhibitors. The trial is a dose-escalation study, meaning researchers are carefully testing increasing doses to find the right balance of safety and activity. First proof-of-concept data are expected later in 2026.

That timeline matters. Lilly is paying up to $2.3 billion before seeing whether the drug actually works in people. Preclinical data in animal models is promising, but biotech history is littered with drugs that looked spectacular in mice and failed spectacularly in humans. The milestone-based structure of the deal offers some protection (Lilly won't pay the full amount unless the drug hits specific targets), but the upfront commitment is still significant.

A Crowded, Hungry Market

Lilly isn't the only one eyeing better myelofibrosis treatments. The field is buzzing with new approaches. Pelabresib, a BET inhibitor, showed improved results when combined with ruxolitinib in the Phase III MANIFEST-2 trial. Imetelstat (branded Rytelo) has a survival analysis expected in the second half of 2026. And selinexor, which works through a completely different mechanism, was expected to report Phase 3 data earlier this year.

Then there are mutation-directed therapies targeting calreticulin (CALR), a genetic driver found in approximately 70% of JAK2/MPL-negative myeloproliferative neoplasm cases. The whole landscape is shifting from "manage symptoms and hope for the best" toward actual disease modification.

AJ1-11095 would need to prove it belongs in this increasingly competitive field. Being first-in-class (the only Type II JAK2 inhibitor) is an advantage, but only if the clinical data back up the preclinical story.

The Bottom Line

Lilly is making a calculated gamble that the science of JAK inhibition isn't finished; it just needs a better version. The Type II mechanism is genuinely novel, the preclinical data are encouraging, and the unmet need in myelofibrosis is painfully real.

But $2.3 billion is a lot of money for a Phase 1 asset with no human data. Lilly can afford it (tirzepatide generated $36.5 billion in revenue in 2025), and the milestone structure cushions the blow. Still, this deal lives or dies on what those first clinical readouts show later this year.

For myelofibrosis patients who've run out of options, the stakes are even higher. They don't need another drug that shrinks their spleen for a while. They need one that changes the trajectory of their disease. Whether AJ1-11095 can deliver on that promise is the billion-dollar question, literally.

The Kidney Drug That Wasn't Supposed to Get Approved

Filspari just became the first FDA-approved treatment for FSGS, a rare kidney disease that's been without an approved therapy forever. The twist? The pivotal trial technically missed its main goal. How Travere pulled off the approval anyway is a story worth reading.